Kevin Sayer describes Dexcom‘s (NSDQ:DXCM) history as punctuated by “firsts” – its continuous glucose meter was the first to connect to a phone. Last year, the company’s tool became the first to be approved by the FDA as one from which a patient with diabetes can make insulin dosing decisions.
When Sayer took the helm as president & CEO of Dexcom in 2011, he was no stranger to the diabetes space. He served as the CFO of MiniMed from 1994 until it was bought by Medtronic (NYSE:MDT) in 2001, at which point he joined the medtech giant’s diabetes business.
“I’ve always felt that continuous glucose monitoring is what really unlocks the door to the best possible outcomes you can have in treating diabetes across the board and those convictions have only increased as we’ve developed our technology here at Dexcom,” Sayer told Drug Delivery Business News. “The technology is so much better than what it was before and has the potential to be even much stronger than what it is now.”
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom CEO: Bringing meaningful data to the diabetes community appeared first on MassDevice.
from MassDevice http://ift.tt/2xE3jTW
Cap comentari:
Publica un comentari a l'entrada